Invitrogen

PTEN Polyclonal Antibody

Advanced Verification

IP-mass spectrometry

12 Published Figures

17 References

View all (24) PTEN antibodies

Datasheet

Protocols

Questions & Answers

Tech Support

Datasheet

Protocols

Questions & Answers

Tech Support

PTEN Antibody in Immunohistochemistry (Paraffin) (IHC (P))

FIGURE: 1 / 19

PTEN Antibody (51-2400) in IHC (P)

Immunohistochemistry analysis of PTEN showing staining in the cytoplasm and nucleus of paraffin-embedded human breast carcinoma (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room t... View More

PTEN Antibody in Immunohistochemistry (IHC)

PTEN Antibody in Western Blot, Immunoprecipitation (WB, IP)

Product Image Gallery

PTEN Antibody — IP-MS enrichment of PTEN (LFQ intensity): PTEN was enriched 169-fold from MCF7 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Product # 90409) and PTEN antibody (Product # 51-2400). See more information on IP-MS verification of antibody selectivity. {IP-MS}

Product Details

51-2400

Applications

Tested Dilution

Publications

Western Blot (WB)

1-3 µg/mL

View 4 publications 4 publications

Immunohistochemistry (IHC)

View 8 publications 8 publications

Immunohistochemistry (Paraffin) (IHC (P))

1:50-1:500

View 4 publications 4 publications

ELISA (ELISA)

0.1-1.0 µg/mL

Immunoprecipitation (IP)

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human, Mouse

Published species

Human, Mouse

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

A 22 amino acid synthetic peptide derived from the carboxy-terminus of the human PTEN protein. This sequence is 100% conserved with the dog PTEN protein and differs by only one amino acid from the rat and mouse PTEN proteins

View immunogen

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.25 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS, pH 7.4

Contains

0.1% sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2533901

Target Information

PTEN was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The PTEN gene is a phosphatidylinositol-3, 4, 5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. PTEN negatively regulates intracellular levels of phosphatidylinositol-3, 4, 5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. PTEN plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Also, PTEN may be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form of PTEN induces less tumor suppressive ability.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Hyperphosphorylated PTEN exerts oncogenic properties.

Nature communications

van Ree JH,Jeganathan KB,Fierro Velasco RO,Zhang C,Can I,Hamada M,Li H,Baker DJ,van Deursen JM

51-2400 was used in Western Blotting to suggest that C-tail hyperphosphorylation creates oncogenic PTEN and is a potential target for anti-cancer therapy.

Wed May 24 00:00:00 EDT 2023

Hyperphosphorylated PTEN exerts oncogenic properties.

Nature communications

van Ree JH,Jeganathan KB,Fierro Velasco RO,Zhang C,Can I,Hamada M,Li H,Baker DJ,van Deursen JM

51-2400 was used in Western Blotting to suggest that C-tail hyperphosphorylation creates oncogenic PTEN and is a potential target for anti-cancer therapy.

Wed May 24 00:00:00 EDT 2023

Hyperphosphorylated PTEN exerts oncogenic properties.

Nature communications

van Ree JH,Jeganathan KB,Fierro Velasco RO,Zhang C,Can I,Hamada M,Li H,Baker DJ,van Deursen JM

51-2400 was used in Western Blotting to suggest that C-tail hyperphosphorylation creates oncogenic PTEN and is a potential target for anti-cancer therapy.

Wed May 24 00:00:00 EDT 2023

Hyperphosphorylated PTEN exerts oncogenic properties.

Nature communications

van Ree JH,Jeganathan KB,Fierro Velasco RO,Zhang C,Can I,Hamada M,Li H,Baker DJ,van Deursen JM

51-2400 was used in Western Blotting to suggest that C-tail hyperphosphorylation creates oncogenic PTEN and is a potential target for anti-cancer therapy.

Wed May 24 00:00:00 EDT 2023

The Effect of Atm Loss on Radiosensitivity of a Primary Mouse Model of Pten-Deleted Brainstem Glioma.

Cancers

Stewart CE,Guerra-García ME,Luo L,Williams NT,Ma Y,Regal JA,Ghosh D,Sansone P,Oldham M,Deland K,Becher OJ,Kirsch DG,Reitman ZJ

51-2400 was used in ELISA, Immunohistochemistry (Paraffin), Western Blot to show that deletion of Atm in the tumor cells does not extend survival of mice bearing Pten-null brainstem gliomas after focal brain irradiation.

Sat Sep 17 00:00:00 EDT 2022

The Effect of Atm Loss on Radiosensitivity of a Primary Mouse Model of Pten-Deleted Brainstem Glioma.

Cancers

Stewart CE,Guerra-García ME,Luo L,Williams NT,Ma Y,Regal JA,Ghosh D,Sansone P,Oldham M,Deland K,Becher OJ,Kirsch DG,Reitman ZJ

Sat Sep 17 00:00:00 EDT 2022

The Novel Phosphatase Domain Mutations Q171R and Y65S Switch PTEN from Tumor Suppressor to Oncogene.

Cells

Garrido JAMG,Alcantara KMM,Danac JMC,Serrano FEC,Cutiongco-de la Paz EM,Garcia RL

Published figure using PTEN polyclonal antibody (Product # 51-2400) in Western Blot

Sun Dec 05 00:00:00 EST 2021

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer.

Life (Basel, Switzerland)

Prvanović M,Nedeljković M,Tanić N,Tomić T,Terzić T,Milovanović Z,Maksimović Z,Tanić N

51-2400 was used in Immunohistochemistry to investigate the PI3K/PTEN/Akt/mTOR pathway as one of the most frequently deregulated pathways in cancer.

Wed Nov 17 00:00:00 EST 2021

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer.

Life (Basel, Switzerland)

Prvanović M,Nedeljković M,Tanić N,Tomić T,Terzić T,Milovanović Z,Maksimović Z,Tanić N

51-2400 was used in Immunohistochemistry to investigate the PI3K/PTEN/Akt/mTOR pathway as one of the most frequently deregulated pathways in cancer.

Wed Nov 17 00:00:00 EST 2021

Melatonin ameliorates renal fibroblast-myofibroblast transdifferentiation and renal fibrosis through miR-21-5p regulation.

Journal of cellular and molecular medicine

Li N,Wang Z,Gao F,Lei Y,Li Z

Published figure using PTEN polyclonal antibody (Product # 51-2400) in Western Blot

Fri May 01 00:00:00 EDT 2020

EphA2, a possible target of miR-200a, functions through the AKT2 pathway in human lung carcinoma.

International journal of clinical and experimental pathology

Tsubochi H,Minegishi K,Goto A,Nakamura R,Matsubara D,Dobashi Y

51-2400 was used in Immunohistochemistry to show that EphA2 may be a target of miR-200a in AC and in pStage I/II cancers that exhibit AKT2 CNI.

Wed Sep 16 00:00:00 EDT 2020

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

Nature genetics

Chen J,Guccini I,Di Mitri D,Brina D,Revandkar A,Sarti M,Pasquini E,Alajati A,Pinton S,Losa M,Civenni G,Catapano CV,Sgrignani J,Cavalli A,D'Antuono R,Asara JM,Morandi A,Chiarugi P,Crotti S,Agostini M,Montopoli M,Masgras I,Rasola A,Garcia-Escudero R,Delaleu N,Rinaldi A,Bertoni F,Bono J,Carracedo A,Alimonti A

51-2400 was used in Immunohistochemistry on paraffin embedded tissues to study the mechanisms by which mitochondrial metabolism supports cancer anabolism.

Thu Feb 01 00:00:00 EST 2018

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

Nature

Zabala-Letona A,Arruabarrena-Aristorena A,Martín-Martín N,Fernandez-Ruiz S,Sutherland JD,Clasquin M,Tomas-Cortazar J,Jimenez J,Torres I,Quang P,Ximenez-Embun P,Bago R,Ugalde-Olano A,Loizaga-Iriarte A,Lacasa-Viscasillas I,Unda M,Torrano V,Cabrera D,van Liempd SM,Cendon Y,Castro E,Murray S,Revandkar A,Alimonti A,Zhang Y,Barnett A,Lein G,Pirman D,Cortazar AR,Arreal L,Prudkin L,Astobiza I,Valcarcel-Jimenez L,Zuñiga-García P,Fernandez-Dominguez I,Piva M,Caro-Maldonado A,Sánchez-Mosquera P,Castillo-Martín M,Serra V,Beraza N,Gentilella A,Thomas G,Azkargorta M,Elortza F,Farràs R,Olmos D,Efeyan A,Anguita J,Muñoz J,Falcón-Pérez JM,Barrio R,Macarulla T,Mato JM,Martinez-Chantar ML,Cordon-Cardo C,Aransay AM,Marks K,Baselga J,Tabernero J,Nuciforo P,Manning BD,Marjon K,Carracedo A

51-2400 was used in Immunohistochemistry to show that mechanistic target of rapamycin complex 1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity.

Thu Jul 06 00:00:00 EDT 2017

Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.

Nature communications

Revandkar A,Perciato ML,Toso A,Alajati A,Chen J,Gerber H,Dimitrov M,Rinaldi A,Delaleu N,Pasquini E,D'Antuono R,Pinton S,Losa M,Gnetti L,Arribas A,Fraering P,Bertoni F,Nepveu A,Alimonti A

512400 was used in immunohistochemistry - paraffin section to demonstrate that PTEN loss results in ADAM17 and NOTCH signaling in prostate cancer cells

Mon Dec 12 00:00:00 EST 2016

Immunopathologic Assessment of PTEN Expression.

Methods in molecular biology (Clifton, N.J.)

Castillo-Martin M,Thin TH,Collazo Lorduy A,Cordon-Cardo C

51-2400 was used in immunohistochemistry - paraffin section to assess PTEN expression by immunopathology

Tue Dec 13 00:00:00 EST 2016

Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.

Cell reports

Toso A,Revandkar A,Di Mitri D,Guccini I,Proietti M,Sarti M,Pinton S,Zhang J,Kalathur M,Civenni G,Jarrossay D,Montani E,Marini C,Garcia-Escudero R,Scanziani E,Grassi F,Pandolfi PP,Catapano CV,Alimonti A

51-2400 was used in Immunohistochemistry on paraffin embedded tissues to demonstrate that immune surveillance of senescent tumour cells can be suppressed in specific genetic backgrounds but also evoked by pharmacological treatments.

Thu Oct 09 00:00:00 EDT 2014

Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Zu K,Martin NE,Fiorentino M,Flavin R,Lis RT,Sinnott JA,Finn S,Penney KL,Ma J,Fazli L,Gleave ME,Bismar TA,Stampfer MJ,Pollak MN,Loda M,Mucci LA,Giovannucci E

Fri Nov 01 00:00:00 EDT 2013

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research

Lotan TL,Gurel B,Sutcliffe S,Esopi D,Liu W,Xu J,Hicks JL,Park BH,Humphreys E,Partin AW,Han M,Netto GJ,Isaacs WB,De Marzo AM

51-2400 was used in immunohistochemistry to test if loss of PTEN protein is associated with poor outcomes for patients with prostate cancer.

Sat Oct 15 00:00:00 EDT 2011

Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.

Science signaling

Poliseno L,Salmena L,Riccardi L,Fornari A,Song MS,Hobbs RM,Sportoletti P,Varmeh S,Egia A,Fedele G,Rameh L,Loda M,Pandolfi PP

51-2400 was used in Immunohistochemistry to uncover a proto-oncogenic microRNA-dependent network for phosphatase and tensin homologue deleted on chromosome 10 regulation and defined the MCM7 locus as critical in initiating prostate tumourigenesis.

Tue Apr 13 00:00:00 EDT 2010

Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphatidylinositol 3'-phosphate kinase/PTEN pathway.

Cancer research

Jimenez AI,Fernandez P,Dominguez O,Dopazo A,Sanchez-Cespedes M

Sat Mar 15 00:00:00 EST 2003

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

Clinical cancer research : an official journal of the American Association for Cancer Research

Soria JC,Lee HY,Lee JI,Wang L,Issa JP,Kemp BL,Liu DD,Kurie JM,Mao L,Khuri FR

Wed May 01 00:00:00 EDT 2002

Bioinformatics

Protein Aliases: Inositol polyphosphate 3-phosphatase; mitochondrial phosphatase and tensin protein alpha; mitochondrial PTENalpha; MMAC1 phosphatase and tensin homolog deleted on chromosome 10; Mutated in multiple advanced cancers 1; Phosphatase and tensin homolog; phosphatase and tensin-like protein; phosphatidylinositol 3; Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; phosphatidylinositol-3; phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; pten tumor suppressor

View more View less

Gene Aliases: 10q23del; 2310035O07Rik; A130070J02Rik; AI463227; B430203M17Rik; BZS; CWS1; DEC; GLM2; MHAM; MMAC1; PTEN; PTEN1; TEP1

View more View less

UniProt ID: (Human) P60484, (Mouse) Q542G1

View more View less

Entrez Gene ID: (Human) 5728, (Mouse) 19211

View more View less

Function(s)

Process(es)

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

PTEN Polyclonal Antibody

PTEN Antibody (51-2400) in IHC (P)

Product Details

51-2400

Western Blot (WB)

Immunohistochemistry (IHC)

Immunohistochemistry (Paraffin) (IHC (P))

ELISA (ELISA)

Immunoprecipitation (IP)

Species Reactivity

Published species

Host/Isotype

Class

Type

Immunogen

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!